Home › Targets › mTOR
mTOR (2 companies · 10 programs)
Companies with an active program directed at mTOR.
- paxalisib — Glioblastoma Phase 2
- paxalisib — Triple-Negative Breast Cancer Phase 1
- paxalisib — Diffuse Intrinsic Pontine Glioma Phase 2
- paxalisib — Atypical Rhabdoid/Teratoid Tumors Phase 2
- paxalisib — Colorectal Cancer Preclinical
- paxalisib — Epilepsy Phase 1
- paxalisib — Primary Central Nervous System Lymphoma Phase 2
- paxalisib — Brain Metastases Phase 2
- paxalisib — IDH-Mutant Glioma Phase 2